These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 30641926)

  • 1. Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1.
    Wagner KD; El Maï M; Ladomery M; Belali T; Leccia N; Michiels JF; Wagner N
    Cells; 2019 Jan; 8(1):. PubMed ID: 30641926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.
    Amin EM; Oltean S; Hua J; Gammons MV; Hamdollah-Zadeh M; Welsh GI; Cheung MK; Ni L; Kase S; Rennel ES; Symonds KE; Nowak DG; Royer-Pokora B; Saleem MA; Hagiwara M; Schumacher VA; Harper SJ; Hinton DR; Bates DO; Ladomery MR
    Cancer Cell; 2011 Dec; 20(6):768-80. PubMed ID: 22172722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1.
    Belali T; Wodi C; Clark B; Cheung MK; Craig TJ; Wheway G; Wagner N; Wagner KD; Roberts S; Porazinski S; Ladomery M
    Biochim Biophys Acta Gene Regul Mech; 2020 Dec; 1863(12):194642. PubMed ID: 33017668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
    Supradit K; Boonsri B; Duangdara J; Thitiphatphuvanon T; Suriyonplengsaeng C; Kangsamaksin T; Janvilisri T; Tohtong R; Yacqub-Usman K; Grabowska AM; Bates DO; Wongprasert K
    Toxicol In Vitro; 2022 Aug; 82():105385. PubMed ID: 35568131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.
    Mavrou A; Brakspear K; Hamdollah-Zadeh M; Damodaran G; Babaei-Jadidi R; Oxley J; Gillatt DA; Ladomery MR; Harper SJ; Bates DO; Oltean S
    Oncogene; 2015 Aug; 34(33):4311-9. PubMed ID: 25381816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
    Gammons MV; Lucas R; Dean R; Coupland SE; Oltean S; Bates DO
    Br J Cancer; 2014 Jul; 111(3):477-85. PubMed ID: 25010863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.
    Oltean S; Gammons M; Hulse R; Hamdollah-Zadeh M; Mavrou A; Donaldson L; Salmon AH; Harper SJ; Ladomery MR; Bates DO
    Biochem Soc Trans; 2012 Aug; 40(4):831-5. PubMed ID: 22817743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain.
    Hulse RP; Drake RA; Bates DO; Donaldson LF
    Neurobiol Dis; 2016 Dec; 96():186-200. PubMed ID: 27616424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy.
    Malhi NK; Allen CL; Stewart E; Horton KL; Riu F; Batson J; Amoaku W; Morris JC; Arkill KP; Bates DO
    Am J Physiol Heart Circ Physiol; 2022 Jun; 322(6):H1014-H1027. PubMed ID: 35302878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LTR retrotransposon-derived LncRNA LINC01446 promotes hepatocellular carcinoma progression and angiogenesis by regulating the SRPK2/SRSF1/VEGF axis.
    Wu Y; Wang J; Zhao J; Su Y; Li X; Chen Z; Wu X; Huang S; He X; Liang L
    Cancer Lett; 2024 Aug; 598():217088. PubMed ID: 38945203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SRPK1/2 and PP1α exert opposite functions by modulating SRSF1-guided MKNK2 alternative splicing in colon adenocarcinoma.
    Liu H; Gong Z; Li K; Zhang Q; Xu Z; Xu Y
    J Exp Clin Cancer Res; 2021 Feb; 40(1):75. PubMed ID: 33602301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway.
    Thorsen K; Mansilla F; Schepeler T; Øster B; Rasmussen MH; Dyrskjøt L; Karni R; Akerman M; Krainer AR; Laurberg S; Andersen CL; Ørntoft TF
    Mol Cell Proteomics; 2011 Jan; 10(1):M110.002998. PubMed ID: 20938052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform.
    Hatcher JM; Wu G; Zeng C; Zhu J; Meng F; Patel S; Wang W; Ficarro SB; Leggett AL; Powell CE; Marto JA; Zhang K; Ki Ngo JC; Fu XD; Zhang T; Gray NS
    Cell Chem Biol; 2018 Apr; 25(4):460-470.e6. PubMed ID: 29478907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells.
    Jia T; Jacquet T; Dalonneau F; Coudert P; Vaganay E; Exbrayat-Héritier C; Vollaire J; Josserand V; Ruggiero F; Coll JL; Eymin B
    BMC Biol; 2021 Aug; 19(1):173. PubMed ID: 34433435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.
    Wahid M; Pratoomthai B; Egbuniwe IU; Evans HR; Babaei-Jadidi R; Amartey JO; Erdelyi V; Yacqub-Usman K; Jackson AM; Morris JC; Patel PM; Bates DO
    Cancer Immunol Immunother; 2023 Dec; 72(12):4001-4014. PubMed ID: 37973660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.
    Nowak DG; Amin EM; Rennel ES; Hoareau-Aveilla C; Gammons M; Damodoran G; Hagiwara M; Harper SJ; Woolard J; Ladomery MR; Bates DO
    J Biol Chem; 2010 Feb; 285(8):5532-40. PubMed ID: 19906640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.
    Batson J; Toop HD; Redondo C; Babaei-Jadidi R; Chaikuad A; Wearmouth SF; Gibbons B; Allen C; Tallant C; Zhang J; Du C; Hancox JC; Hawtrey T; Da Rocha J; Griffith R; Knapp S; Bates DO; Morris JC
    ACS Chem Biol; 2017 Mar; 12(3):825-832. PubMed ID: 28135068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD.
    Gammons MV; Fedorov O; Ivison D; Du C; Clark T; Hopkins C; Hagiwara M; Dick AD; Cox R; Harper SJ; Hancox JC; Knapp S; Bates DO
    Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6052-62. PubMed ID: 23887803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells.
    Gonçalves V; Henriques AF; Pereira JF; Neves Costa A; Moyer MP; Moita LF; Gama-Carvalho M; Matos P; Jordan P
    RNA; 2014 Apr; 20(4):474-82. PubMed ID: 24550521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The predominant WT1 isoform (+KTS) encodes a DNA-binding protein targeting the planar cell polarity gene Scribble in renal podocytes.
    Wells J; Rivera MN; Kim WJ; Starbuck K; Haber DA
    Mol Cancer Res; 2010 Jul; 8(7):975-85. PubMed ID: 20571064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.